“Biotech is climate tech” is the message of today's new episode of the I am BIO Podcast—plus, a BIO member’s promising drug targeting an ultra-rare disease with unmet need will get FDA review. (517 words, 2 minutes, 35 seconds)
Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech.
It’s all about platform technology today—from a platform developing animal-free meat and dairy and innovative de-icing technology, to how platform technology can drive rare disease R&D. (558 words, 2 minutes, 47 seconds)
Capital Formation Policy Issues, ECS Digital Resources • April 7, 2024
Comments on proposed rule to require information about a registrant’s climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition.
Today, we recap the World Vaccine Congress in Washington, D.C., and look at a recent report highlighting the economic and environmental benefits of biobased products. Enjoy the weekend. (532 words, 2 minutes, 39 seconds)
The Committee concentrates on tax, financial services, securities, and accounting policies that impact member companies and biotech capital formation. This committee advises BIO staff about the impact of legislation and regulations affecting these policy matters and supports BIO’s engagement with Treasury, the SEC, and the IRS, as well as Congress and the Administration.
For more information and to join the Committee, please contact Emily Berst (eberst@bio.org).
